Physiomics Share News (PYC)

Physiomics Information

Buy PYC Shares
Add PYC to Watchlist
Add PYC to Alert

Share Price Information for Physiomics (PYC)

Share Price is delayed by 15 minutes

Get Live Data

Share Price: 1.30

Bid: 1.20

Ask: 1.40

Change: -0.20 (-13.33%)

Spread: 0.20 (16.667%)

Open: 1.25

High: 1.30

Low: 1.05

Prev. Close: 1.50

Last checked at -

IN BRIEF: Physiomics wins first contract from Numab Therapeutics

Tue, 11th May 2021 17:50

Physiomics PLC - oncology consultant based in Oxford - Awarded its first contract by Zurich-based biopharmaceutical company Numab Therapeutics, which is focused on developing biotherapeutics for chronic inflammation and cancer.

"We are delighted that Numab has selected Physiomics to support them with one of their new programs and look forward to working with their highly talented team," notes Chief Executive Officer Jim Millen.

Current stock price: 5.91 pence

Year-to-date change: down 20%

By Dayo Laniyan; dayolaniyan@alliancenews.com

More News

2 Mar 2022 20:28

TRADING UPDATES: MediaZest virus hit; SpaceandPeople Network Rail deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

23 Feb 2022 14:48

IN BRIEF: Physiomics chair steps down after 15 years; CEO adds role

Physiomics PLC - oncology consultancy based in Oxford, England - Non-Executive Chair Paul Harper steps down from board immediately, having served on the board since 2004 and as chair since 2007. Chief Executive Officer Jim Millen will take on the additional role of executive chair. Physiomics also will recruit one independent non-executive director "as soon as possible".

21 Feb 2022 14:31

IN BRIEF: Physiomics shares up on continued DoseMeRx collaboration

Physiomics PLC - oncology consultancy based in Oxford - Confirms it will continue to collaborate with DoseMeRx, after Tabula Rasa Healthcare Inc announces it will sell DoseMeRx. The collaboration will explore further commercial opportunities in cancer field. Over 2021, Physiomics' personalised dosing application for docetaxel prostate cancer treatment was integrated into DoseMeRx platform, and was met with positive feedback.

22 Dec 2021 21:22

Latest Share Chat

Physiomics Share News (PYC)

Share Price Information for Physiomics (PYC)

IN BRIEF: Physiomics wins first contract from Numab Therapeutics

TRADING UPDATES: MediaZest virus hit; SpaceandPeople Network Rail deal

IN BRIEF: Physiomics chair steps down after 15 years; CEO adds role

IN BRIEF: Physiomics shares up on continued DoseMeRx collaboration

TRADING UPDATES: Mercia buys more Intechnica; Anexo scores VW win

IN BRIEF: Physiomics signs new deals with Merck worth GBP300,000

Physiomics signs £0.3m of new agreements with Merck

UK shareholder meetings calendar - next 7 days

IN BRIEF: Physiomics pens further deals with Merck KGaA

Physiomics awarded further contracts with Merck

EARNINGS UPDATES: Northbridge "delighted"; Echo Energy loss narrows

UK earnings, trading statements calendar - next 7 days

IN BRIEF: Physiomics recruits first patient for Partner study

TRADING UPDATES: Arkle spots gold; SDCL seals USD177 million buy

AIM WINNERS & LOSERS: Arkle finds gold; Staffline raises cash

Physiomics inks further contracts with Bicycle Therapeutics

Latest Share Chat

Physiomics Share News (PYC)

Share Price Information for Physiomics (PYC)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IN BRIEF: Physiomics wins first contract from Numab Therapeutics

Login to your account

Quickpicks are a member only feature

Login to your account